The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Genetic determinants of long-term response to rapalog therapy in advanced renal cell carcinoma (RCC).
Martin Henner Voss
No relevant relationships to disclose
Abraham A. Hakimi
No relevant relationships to disclose
Sasinya N. Scott
No relevant relationships to disclose
Shugaku Takeda
No relevant relationships to disclose
Han Liu
No relevant relationships to disclose
Yingbei Chen
No relevant relationships to disclose
Robert John Motzer
Consultant or Advisory Role - Pfizer
Research Funding - Novartis; Pfizer
Michael F. Berger
No relevant relationships to disclose
James Hsieh
No relevant relationships to disclose